Results 131 to 140 of about 143,882 (299)

Prothrombin Time and Coagulation Factor IX as Hemostatic Risk Markers for Legg- Calvé-Perthes Disease. [PDF]

Clin Appl Thromb Hemost, 2023
Hernández-Zamora E, Rodríguez-Olivas AO, Rosales-Cruz E, Galicia-Alvarado MA, Zavala-Hernández C, Reyes-Maldonado E.   +5 more
europepmc   +1 more source

Flow dilution effect on blood coagulation in vivo [PDF]

Enzyme reaction model of flow dilution effect on blood coagulation in ...
Hu, C.
core   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

Coagulation disorders after reperfusion of pancreatic allografts [PDF]

, 1993
Blumenstock, I., Büsing, M., Heimburger, N., Hopt, U. T., Jochum, Marianne, Nader, A.   +5 more
core   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Retracted: Polymethyl Methacrylate-Based Smart Microfluidic Point-of-Care Testing of Prothrombin Time and International Normalized Ratio through Optical Detection. [PDF]

Comput Math Methods Med, 2023
Methods In Medicine CAM.
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Congenital Factor X-Riyadh (Stuart-Prower) Deficiency With Isolated Prothrombin Time Prolongation: A Case Report. [PDF]

Cureus, 2023
Alasmari BG, Tahaelbashir SE, Alomari M, Hommadi AM, Baothman A, Al-Tala SM.   +5 more
europepmc   +1 more source

Prothrombin Time [PDF]

, 2020
openaire   +1 more source

Machine Learning Approach Enables Highly Accurate Identification of At‐Risk Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
ABSTRACT Aim At‐risk metabolic dysfunction‐associated steatohepatitis (MASH), characterized by significant activity and fibrosis, increases the risk of liver complications. Liver stiffness measurement (LSM), commonly used to detect significant fibrosis, has limitations in terms of accessibility and performance in certain populations.
Masaya Sato, Takuma Nakatsuka, Tatsuya Minami, Yotaro Kudo, Rie Irie, Hanako Tsujikawa, Takumi Kawaguchi, Hirokazu Takahashi, Yuichiro Eguchi, Eisuke Murakami, Kazuaki Chayama, Takeshi Okanoue, Michiie Sakamoto, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +15 more
wiley   +1 more source